Last reviewed · How we verify

Taisho Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief

Taisho Pharmaceutical Co., Ltd. pipeline: 2 marketed, 0 filed, 4 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 4 Phase 3 3 Phase 2 7 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Loqoa ESFLURBIPROFEN marketed Prostaglandin G/H synthase 2 Immunology 2015-01-01
Nanozora OZORALIZUMAB marketed Tumor necrosis factor Oncology
Placebo to TS-142 Placebo to TS-142 phase 3
TS-152 TS-152 phase 3 SGLT2 inhibitor SGLT2 Diabetes
Diclofenac diethylamine Diclofenac diethylamine phase 3 Nonsteroidal anti-inflammatory drug (NSAID) Cyclooxygenase-1 (COX-1), Cyclooxygenase-2 (COX-2) Pain Management, Rheumatology, Inflammation
TS-172 TS-172 phase 3 Serotonin receptor antagonist 5-HT2A receptor Psychiatry

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. GlaxoSmithKline · 2 shared drug classes
  2. Sanofi · 2 shared drug classes
  3. Bayer · 2 shared drug classes
  4. Abbott · 2 shared drug classes
  5. London School of Hygiene and Tropical Medicine · 2 shared drug classes
  6. Pfizer · 2 shared drug classes
  7. Addpharma Inc. · 2 shared drug classes
  8. Shire · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Taisho Pharmaceutical Co., Ltd.:

Cite this brief

Drug Landscape (2026). Taisho Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/taisho-pharmaceutical-co-ltd. Accessed 2026-05-16.

Related